Sophia Lu

Sophia Lu

Auto-generated profile, based on publicly available information

Sophia Lu

Boston University School of Public Health, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2023 in European Urology Oncology
Verified
Journal Article
Open access
RTRonald Tutrone
Ronald Tutrone
Fred SaadFred Saad
Fred Saad
DGDaniel James George
Daniel James George
BTBertrand TOMBAL
Bertrand TOMBAL
JBJames L. Bailen
James L. Bailen
NSNeil Shore
Neil Shore
In the HERO study, relugolix demonstrated sustained testosterone suppression superior to that of leuprolide acetate (97% vs 89%; difference 7.9% [95% confidence interval, 4.1-12%; p < 0.001]). To analyze testosterone recovery in a prespecified subset of men from the HERO study not indicated to continue androgen deprivation therapy. Men (N = 934) were randomized (2:1) to receive relugolix 120 mg orally daily or leuprolide acetate injections every 12 wk for 48 wk. Testosterone recovery was assessed in 184 men who completed 48 wk of treatment. During the 90-d recovery period, assessments included time to testosterone recovery (>280 ng/dl; ≥80% of baseline testosterone), serum levels of prostate-specific antigen and pituitary hormones, and adverse events. The cumulative incidence rate of testosterone recovery to >280 ng/dl at 90 d following drug discontinuation was significantly higher in the relugolix cohort (n = 137) than in the leuprolide acetate cohort (n = 47; 54% vs 3.2%; nominal p = 0.002). The median time to testosterone recovery was faster following relugolix treatment than with leuprolide acetate treatment (86.0 d vs 112.0 d). Compared with leuprolide acetate, more men treated with relugolix achieved ≥80% of baseline testosterone levels (39% vs 2.1%). Men ≤65 yr and those with baseline testosterone greater than the median had a higher incident rate of testosterone recovery. Adverse events were generally similar between treatment groups. One limitation is the short testosterone recovery follow-up period. Oral relugolix had faster and more complete recovery of testosterone to normal levels after treatment discontinuation than leuprolide acetate in a subset of men from the HERO study. The clinical implications of a faster testosterone recovery with relugolix may be significant for men being treated with androgen deprivation therapy and influence treatment decisions. The male hormone testosterone is reduced during androgen deprivation therapy for prostate cancer. Reduced testosterone levels cause side effects, impacting patient quality of life. When treatment is stopped, the side effects lessen over time as the levels of testosterone come back to pretreatment range (testosterone recovery). In this study, we found that the time to testosterone recovery was faster with relugolix than with leuprolide acetate.

22 December 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
HDHuitong Ding
Huitong Ding
AMAmiya Mandapati
Amiya Mandapati
CKCody Karjadi
Cody Karjadi
TATing Fang Alvin Ang
Ting Fang Alvin Ang
SLSophia Lu
Sophia Lu
HLHonghuang Lin
Honghuang Lin
Background: Human voice has increasingly been recognized as an effective indicator for the detection of cognitive disorders. However, the association of acoustic features with specific cognitive functions and mild cognitive impairment (MCI) has yet to be evaluated in a large community-based population. Objective: This study aimed to investigate the association between acoustic features and neuropsychological (NP) tests across multiple cognitive domains and evaluate the added predictive power of acoustic composite scores for the classification of MCI. Methods: This study included participants without dementia from the Framingham Heart Study, a large community-based cohort with longitudinal surveillance for incident dementia. For each participant, 65 low-level acoustic descriptors were derived from voice recordings of NP test administration. The associations between individual acoustic descriptors and 18 NP tests were assessed with linear mixed-effect models adjusted for age, sex, and education. Acoustic composite scores were then built by combining acoustic features significantly associated with NP tests. The added prediction power of acoustic composite scores for prevalent and incident MCI was also evaluated. Results: The study included 7874 voice recordings from 4950 participants (age: mean 62, SD 14 years; 4336/7874, 55.07% women), of whom 453 were diagnosed with MCI. In all, 8 NP tests were associated with more than 15 acoustic features after adjusting for multiple testing. Additionally, 4 of the acoustic composite scores were significantly associated with prevalent MCI and 7 were associated with incident MCI. The acoustic composite scores can increase the area under the curve of the baseline model for MCI prediction from 0.712 to 0.755. Conclusions: Multiple acoustic features are significantly associated with NP test performance and MCI, which can potentially be used as digital biomarkers for early cognitive impairment monitoring.

20 September 2023 in Food & Function
Verified
Journal Article
Closed access
PDF file
SMShirun Ma
Shirun Ma
SLSophia Lu
Sophia Lu
Objective: To examine the associations between bitter taste sensitivity, cruciferous vegetable consumption, and likelihood of obesity and diabetes among American adults. Research design and method: Cross-section observation of 2129 adults aged 40–80 years of the National Health and Nutrition Examination Survey (NHANES) 2013–2014. Bitter taste sensitivity was estimated by the generalized labeled magnitude scale (gLMS) rating for bitterness (non-tasters: the lowest 25%, the others were tasters). Consumption of cruciferous vegetables was recorded by the 2 day 24 hours dietary records. Obesity was defined as body mass index (BMI) ≥30 kg m−2. Diabetes was defined as self-reported physician-diagnosed diabetes, or who reported taking diabetes medication or individuals with a fasting plasma glucose (FPG) ≥ 126 mg dL−1 or Hemoglobin A1c ≥ 6.5%. Results: The proportion of participants who ate cruciferous vegetables over the two days was 29.5% among bitter tasters, significantly lower than that (35.7%) among non-tasters (P = 0.04) after adjustment of age, gender, race/ethnicity, dietary energy intake, physical activity, education, smoking and income levels. Among participants who ate cruciferous vegetables, bitter tasters on average consumed 15.5 g (±7.0) grams less cruciferous vegetables per day compared to non-tasters. The multi-variates adjusted odds ratio of obesity was 1.29 (95% confident interval (CI): 0.76–2.17), 1.40 (95% CI: 0.90–2.18) and 1.68 (95% CI: 1.05–2.67) among bitter tasters who ate cruciferous vegetables, among non-tasters who did not ate cruciferous vegetables, and among bitter tasters who did not eat cruciferous vegetables, respectively, as compared with non-tasters who ate cruciferous vegetables. The prevalence of diabetes was 17.3% and 13.0% among bitter tasters and non-tasters, respectively, with a multi-adjusted odds ratio of 1.32 (95% CI: 1.02–1.69, P = 0.033) for diabetes comparing bitter tasters with non-tasters, which was attenuated to 1.26 (95% CI: 0.95–1.67, P = 0.108) by further adjustment of cruciferous vegetables consumption and obesity, with a mediation effect of 17.8% (95% CI: 2.9%–60.9%; P = 0.069). Conclusion: Bitter taste sensitivity was associated with less consumption of cruciferous vegetables and a high likelihood of obesity, which may mediate its association with diabetes.

25 November 2025 in Neurology
Verified
Journal Article
Closed access
JRJaime Ramos-Cejudo
Jaime Ramos-Cejudo
ABAlexa S. Beiser
Alexa S. Beiser
SLSophia Lu
Sophia Lu
JTJeremy A. Tanner
Jeremy A. Tanner
MSMatthew R. Scott
Matthew R. Scott
SSSudha Seshadri
Sudha Seshadri
Vascular dysfunction contributes to Alzheimer disease (AD) and related dementias (ADRDs), but the underlying mechanisms remain unclear. Previous studies link midlife hemostasis and platelet aggregation measures to late-life dementia risk. We aimed to determine whether platelet aggregation in midlife is associated with imaging markers of AD pathology. In a cross-sectional study, we evaluated associations between platelet aggregation, measured by light transmission aggregometry, and amyloid (11C-Pittsburgh compound B) and tau (18F-flortaucipir) PET uptake in dementia-free, middle-aged adults from the Framingham Heart Study. Co-primary outcomes included amyloid and tau uptake in AD-vulnerable regions. We also examined an MRI-based cortical thickness signature of AD risk as a secondary outcome. We used multivariable regression models adjusted for demographic and clinical factors, considering potential nonlinear associations. Platelet aggregation response was evaluated in 382 participants (mean age 56 ± 8 years, 53% female) approximately 1.2-1.5 years before amyloid and tau PET imaging. MRI data used for the AD signature were acquired together with PET imaging or within several months. The aggregation response exhibited a nonlinear association with AD pathology. Among those in the lowest tertile of adenosine diphosphate (ADP) response, platelet aggregation response was positively associated with increased amyloid in the precuneus (β = 0.047, p = 0.020) and tau in the rhinal (β = 0.077, p = 0.012), entorhinal (β = 0.066, p < 0.020), temporal global (β = 0.063, p = 0.031), and cortical (β = 0.064, p = 0.028) regions. For the secondary outcome analysis (n = 256), platelet aggregation response was negatively associated with the MRI-based cortical thickness signature of AD risk (β = -0.002, p < 0.035), consistent with a neurodegenerative pattern. Our findings indicate that platelet aggregation is linked to PET and MRI markers of AD pathology as early as midlife. These findings support further investigation of platelet-mediated mechanisms in AD pathogenesis.

22 October 2021
Verified
Conference Paper
Open access
PDF file
SLSophia Francesca Lu
Sophia Francesca Lu
Objective Small scale mining (SSM) has contributed 14% of the total Gross Domestic Product (GDP) of the Philippines. The aim of the study is to look into policy issues on work and employment of small scale miners in the Philippines. Methods The data were based on gray literature, peer-reviewed journals, databases, government statistics, and secondary literature on major mining disasters in the Philippines, and the impact of regulation or lack thereof in this industry. Results Research findings show that mining work is artisanal, with use of simple tools, and lack of sophisticated equipment and processes. There is massive use of toxic chemicals such as cyanide and mercury that have been associated with adverse health problems. The study review showed certain health issues due to cyanide and mercury poisoning from mining such as rapid breathing, gasping, tremors, convulsions, headache, dizziness and thyroid enlargement and eventually death, and children ages 17 years old and below experienced cough, wheezing, shortness of breath. In Western Mindanao, workers were found to be exposed to high levels of mercury. Gastrointestinal complaints of the workers were significantly associated with elevated hair methylmercury levels. Despite these, the government has no existing specific regulation and monitoring system for safety and health among small scale miners in the Philippines. Other policy issues included the following-that small scale mining is unregulated and unrecognized, absence of social safety net protection for the sector. Conclusion Based on the research and policy reviews, there is a need to integrate the small scale mining into the labour economy so as to regulate and prevent hazardous work practices.

1 June 2019 in Gut
Verified
Conference Paper
Open access
PDF file
SBSergio Borgia
Sergio Borgia
JDJanet Dearden
Janet Dearden
YLYoav Lurie
Yoav Lurie
SSStephen Shafran
Stephen Shafran
ABAshley Brown
Ashley Brown
EGEdward Gane
Edward Gane
Background Approved HCV treatments for patients on dialysis are associated with complexities including drug-drug interactions, baseline resistance testing and use of ribavirin. Despite higher concentrations of the primary circulating sofosbuvir (SOF) metabolite, GS-331007, in severe renal impairment, real-world cases demonstrated substantial use of SOF-based regimens in this population without safety concerns identified. This study evaluated the safety, efficacy, and pharmacokinetics (PK) of SOF/velpatasvir (VEL) for 12 weeks in patients with HCV infection on dialysis. Methods Treatment-naive or -experienced patients, of any genotype, with or without compensated cirrhosis undergoing hemodialysis or peritoneal dialysis, were enrolled to receive open-label SOF/VEL (400/100 mg) once daily for 12 weeks. The primary efficacy endpoint was a comparison of the SVR12 to a prespecified historic control rate of 83%. The primary safety endpoint was the proportion of patients who discontinued therapy due to adverse events (AEs). Secondary endpoints included safety, viral resistance and PK. Results 59 patients were enrolled at 21 sites in Canada, United Kingdom, Spain, Israel, Australia and New Zealand. The median age was 62 years (range 49–86), 59% were male, 53% white, 32% treatment experienced, 29% had cirrhosis. Most patients had HCV genotype 1 (42%), or 3 (27%). Most (92%) were on hemodialysis with a mean dialysis duration of 7.3 years. Treatment was well tolerated; no one discontinued therapy due to AEs. One patient was discontinued therapy on day 74 for non-compliance with 48% study medication adherence by pill count. Overall, 56/59 (95%) of patients achieved SVR12. Two (3%) had virologic relapse (one with non-adherence). One patient did not achieve SVR12 due to death from suicide after SVR4. Exposures were consistent with the Phase 1 renal impairment study. The most frequent AEs were headache, fatigue, nausea, and vomiting. Serious AEs occurred in 19% of patients, none was assessed as related to study drug. Conclusions Treatment with SOF/VEL for 12 weeks in patients with and without cirrhosis undergoing dialysis resulted in a 95% SVR12 rate. The regimen was safe and well-tolerated with no treatment-related discontinuations or treatment-related SAEs.